Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Liu, Jun Wei ^a   Cai, Min Xia ^b   Xin, Ying ^a   Wu, Qing Song ^a   Ma, Jun ^a   Yang, Po ^a   Xie, Hai Yang ^b   Huang, Dong Sheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; DNA FRAGMENT; PARTHENOLIDE; PROCASPASE 3; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WOUND CLOSURE; CANCER INVASION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NF-KAPPA B; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SESQUITERPENES; TUMOR CELLS, CULTURED;

EID: 77955288887     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-108     Document Type: Article

References (31)

1. Cancer statistics, 2004. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun, CA-Cancer J Clin 2004 54 8 29 10.3322/canjclin.54.1.8 14974761
2. Pancreatic cancer today. MC Safioleas KG Moulakakis, Hepatogastroenterology 2004 51 862 868 15143935
3. NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently a typical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. P Pozarowski DH Halicka Z Parzykiewicz, Cytometry A 2003 54 118 124 10.1002/cyto.a.10057 12879458
4. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. S Zhang CN Ong HM Shen, Cancer Lett 2004 208 143 153 10.1016/j.canlet.2003.11.028 15142672
5. Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. JH Park L Liu IH Kim JH Kim KR You DG Kim, Cancer Res 2005 65 2804 2814 10.1158/0008-5472.CAN-04-2221 15805281
6. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. JH Kim L Liu SO Lee YT Kim KR You DG Kim, Cancer Res 2005 65 6312 6320 10.1158/0008-5472.CAN-04-4193 16024633
7. Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. S Zhang ZN Lin CF Yang X Shi CN Ong HM Shen, Carcinogenesis 2004 25 2191 2199 10.1093/carcin/bgh234 15256485
8. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. H Nakshatri SE Rice P Bhat-Nakshatri, Oncogene 2004 23 7330 7344 10.1038/sj.onc.1207995 15286701
9. Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. YK Won CN Ong X Shi HM Shen, Carcinogenesis 2004 25 1449 1458 10.1093/carcin/bgh151 15033901
10. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. MT Yip-Schneider H Nakshatri CJ Sweeney MS Marshall EA Wiebke CM Schmidt, Mol Cancer Ther 2005 4 587 594 10.1158/1535-7163.MCT-04-0215 15827332
11. Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. JJ Ross JT Arnason HC Birnboim, Planta Med 1999 65 126 129 10.1055/s-1999-13972 10193202
12. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Wen KR You SY Lee CH Song DG Kim, J Biol Chem 2002 277 38954 38964 10.1074/jbc.M203842200 12151389
13. The hallmarks of cancer. D Hanahan RA Weinberg, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
14. Death receptor signaling in cancer therapy. S Fulda KM Debatin, Curr Med Chem Anti-Canc Agents 2003 3 253 262 10.2174/1568011033482404 (Pubitemid 36758300)
15. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. W Wang JL Abbruzzese DB Evans PJ Chiao, Oncogene 1999 18 4554 4563 10.1038/sj.onc.1202833 10467400
16. Stat3 and NF-B activation prevents apoptosis in pancreatic carcinogenesis. FR Greten CK Weber TF Greten G Schneider M Wagner G Adler RM Schmid, Gastroenterology 2002 123 2052 2063 10.1053/gast.2002.37075 12454861
17. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkB kinase. BH Kwok B Koh MI Ndubuisi M Elofsson CM Crews, Chem Biol 2001 8 759 766 10.1016/S1074-5521(01) 00049-7 11514225
18. Effect of celecoxib and the novel anti-cancer agent, dimethylamino- parthenolide, in a developmental model of pancreatic cancer. MT Yip-Schneider H Wu V Njoku M Ralstin B Holcomb PA Crooks S Neelakantan CJ Sweeney CM Schmidt, Pancreas 2008 37 45 e53 10.1097/MPA.0b013e318172b4dd 18815538
19. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. MT Yip-Schneider H Wu M Ralstin C Yiannoutsos PA Crooks S Neelakantan S Noble H Nakshatri CJ Sweeney CM Schmidt, Mol Cancer Ther 2007 6 1736 1744 10.1158/1535-7163.MCT-06-0794 17541034
20. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. W Wang M Adachi R Zhang J Zhou D Zhu, Pancreas 2009 38 114 e123 10.1097/MPA.0b013e3181a0b6f2 19342982
21. The Bcl-2 protein family: Arbiters of cell survival. JM Adams S Cory, Science 1998 281 1322 1326 10.1126/science.281.5381.1322 9735050
22. Bcl-2 family members and the mitochondria in apoptosis. A Gross JM McDonnell SJ Korsmeyer, Gene Dev 1999 13 1899 1911 10.1101/gad.13.15.1899 10444588
23. Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. M Dong JP Zhou H Zhang KJ Guo YL Tian YT Dong, World J G 2005 11 2744 2747 (Pubitemid 40704240)
24. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. CY Wang DC Guttridge MW Mayo AS Baldwin Jr, Mol Cell Biol 1999 19 5923 5929 10454539
25. NF-kB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. JF Kurland R Kodym MD Story KB Spurgers TJ McDonnell RE Meyn, J Biol Chem 2001 276 45380 45386 10.1074/jbc.M108294200 11567031
26. NF-kappa B2/p100 induces Bcl-2 expression. P Viatour M Bentires-Alj A Chariot V Deregowski L de Leval MP Merville V Bours, Leukemia 2003 17 1349 1356 10.1038/sj.leu.2402982 12835724
27. Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. SD Catz JL Johnson, Oncogene 2001 20 7342 7345 10.1038/sj.onc.1204926 11704864
28. Targeting BCL-2 overexpression in various human malignancies through Nf-kappaB inhibition by the proteasome inhibitor bortezomib. BN Fahy MG Schlieman MM Mortenson S Virudachalam RJ Bold, Cancer Chemother Pharmaco1 2005 56 46 54 10.1007/s00280-004-0944-5 (Pubitemid 41201755)
29. Caspases: mtracellular signaling by proteolysis. GS Salvesen VM Dixit, Cell 1997 91 443 446 10.1016/S0092-8674(00)80430-4 9390553
30. Mitochondrial protein that promotes cytochrome-c dependent caspase activation by eliminating IAP inhibition. C Du M Fang Y Li X Wang A Smac, Cell 2000 102 43 53 10.1016/S0092-8674(00)00008-8 10929712
31. An APAF-1.cytochrome-c multimeric complex is a functional apoptosome that activates procaspase-9. H Zou Y Li X Liu X Wang, J Biol Chem 1999 274 11549 11556 10.1074/jbc.274.17.11549 10206961